COVAX following EMA, Britain, on ages for Astrazeneca vaccine - GAVI

·1-min read
FILE PHOTO: Vial and sryinge are seen in front of displayed AstraZeneca logo

GENEVA (Reuters) - The COVAX vaccine facility is aligning with the European Medicines Agency and Britain's Medicines and Healthcare Products Regulatory Agency on age recommendations for use of the AstraZeneca COVID-19 vaccine, the GAVI vaccine alliance said on Wednesday.

The COVID-19 vaccine developed by Oxford University and AstraZeneca gives good immune responses in older people, even if there is a lack of data about its exact efficacy, Oxford's vaccine trial chief Andrew Pollard said earlier.

Seth Berkley, GAVI ceo, told a news conference: "The EMA has actually not restricted this vaccine in terms of age based upon the entire data packages, and of course that is a stringent regulatory authority, nor has the MHRA, another stringent regulatory authority, so we are going with those recommendations."

(Reporting by Stephanie Nebehay in Geneva and Josephine Mason in London; editing by Kate Kelland)